[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,116,428
  • Shares Outstanding, K 212,593
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,131 M
  • EBIT $ -1,182 M
  • EBITDA $ -1,194 M
  • 60-Month Beta 1.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.53

Options Overview Details

View History
  • Implied Volatility 55.58% (+1.84%)
  • Historical Volatility 111.69%
  • IV Percentile 64%
  • IV Rank 19.71%
  • IV High 129.42% on 04/10/26
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 8) 7.37 (5.00%)
  • Put/Call Vol Ratio 0.06
  • Today's Volume 452
  • Volume Avg (30-Day) 11,021
  • Put/Call OI Ratio 1.25
  • Today's Open Interest 149,272
  • Open Int (30-Day) 137,823
  • Expected Range 140.13 to 154.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.75
  • Number of Estimates 9
  • High Estimate $-0.74
  • Low Estimate $-2.03
  • Prior Year $-1.31
  • Growth Rate Est. (year over year) -33.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
94.63 +54.09%
on 04/10/26
155.70 -6.35%
on 04/16/26
+49.53 (+51.44%)
since 04/07/26
3-Month
91.52 +59.33%
on 03/30/26
155.70 -6.35%
on 04/16/26
+48.33 (+49.57%)
since 02/06/26
52-Week
34.00 +328.88%
on 08/07/25
155.70 -6.35%
on 04/16/26
+108.16 (+287.20%)
since 05/07/25

Most Recent Stories

More News
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 144.63 (-4.26%)
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation...

RVMD : 144.63 (-4.26%)
Revolution Medicines: The Daraxonrasib Enthusiasm Before Any Commercial Reality Check

Barchart Research What to Expect from RVMD Earnings RVMD Generated May 5, 2026 Current Price $147.21 EPS Estimate $$-1.83 Consensus Rating Strong Buy Average Move 3.43% Revolution Medicines: The Daraxonrasib...

RVMD : 144.63 (-4.26%)
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REDWOOD CITY, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 144.63 (-4.26%)
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 144.63 (-4.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 159.38
2nd Resistance Point 155.40
1st Resistance Point 153.24
Last Price 144.63
1st Support Level 147.10
2nd Support Level 143.12
3rd Support Level 140.96

See More

52-Week High 155.70
Last Price 144.63
Fibonacci 61.8% 109.21
Fibonacci 50% 94.85
Fibonacci 38.2% 80.49
52-Week Low 34.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.